Evogene reschedules shareholder meeting after no quorum

Evogene Ltd. reported that its Annual General Meeting of Shareholders, originally convened on August 11, 2025, was adjourned for one week due to a lack of quorum, meaning not enough shares were represented to hold a valid meeting.

Rhea-AI Filing Summary

Evogene Ltd. reported that its Annual General Meeting of Shareholders, originally convened on August 11, 2025, was adjourned for one week due to a lack of quorum, meaning not enough shares were represented to hold a valid meeting. The meeting is scheduled to be reconvened on Monday, August 18, 2025 at 3:00 p.m. (Israel time) at the company’s executive offices in Rehovot, Israel.

The report also states that its content is incorporated by reference into Evogene’s existing registration statements on Form F-3 and multiple Form S-8 filings, so this update becomes part of those documents for U.S. securities law purposes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evogene (EVGN) disclose in this Form 6-K?

Evogene disclosed that its Annual General Meeting of Shareholders held on August 11, 2025 was adjourned due to lack of quorum and will be reconvened on August 18, 2025 at its executive offices in Rehovot, Israel.

Why was Evogene’s 2025 Annual General Meeting adjourned?

The Annual General Meeting was adjourned because there was a lack of quorum, meaning an insufficient number of shares were represented to conduct the meeting.

When and where will Evogene’s reconvened Annual General Meeting take place?

The reconvened Annual General Meeting will take place on Monday, August 18, 2025 at 3:00 p.m. (Israel time) at Evogene’s executive offices, 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.

How does this 6-K affect Evogene’s existing registration statements?

The content of this report is incorporated by reference into Evogene’s registration statement on Form F-3 (File No. 333-277565) and its Form S-8 registration statements (File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197).

Does this Form 6-K discuss Evogene’s financial results or major transactions?

No. The report focuses on the scheduling and adjournment of the Annual General Meeting of Shareholders and the incorporation of this information into existing registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 04:01 PM Learn about SEC filing dates

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot

7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

 

On August 11, 2025, Evogene Ltd. (the “Company”) convened its Annual General Meeting of Shareholders (the “Annual Meeting”), however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company’s Annual General Meeting will be reconvened on Monday, August 18, 2025 at 3:00 p.m. (Israel time), at the executive offices of the Company, 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.

The content of this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856, 333-259215 and 333-286197) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 11, 2025 EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer